2022 Editor's Choice

January 2022

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force

Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands

Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer

Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review

February 2022

How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?

Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity

What Constitutes Preferred Long-Term Care Provided in Residential Aged Care Facilities? An Empirical Comparison of the Preferences of the General Population, Residents, and Family Members

Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis

What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks

March 2022

The Value of Artificial Intelligence for Healthcare Decision Making—Lessons Learned

Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities

Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment

April 2022

Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey

Expanding the Scope of Value for Economic Evaluation: The EQ-HWB

The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis

Medicaid Expansion’s Impact on Emergency Department Use by State and Payer

May 2022

Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report

COVID-19 Health Economics: Looking Back and Scoping the Future

Economic Evaluation of Vaccination Programs: A Guide for Selecting Modeling Approaches

The Value of Federated Data Networks in Oncology: What Research Questions Do They Answer? Outcomes From a Systematic Literature Review

June 2022

Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force

Assessing the Value of Remote Patient Monitoring Solutions in Addressing Challenges in Patient Care

Accounting for Intergenerational Cascade Testing in Economic Evaluations of Clinical Genomics: A Scoping Review

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index

Economic Evaluation of Cognitive Behavioral Therapy for Depression: A Systematic Review

July 2022

Machine Learning Methods in Health Economics and Outcomes Research — The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force

Valuing Child Health Isn't Child's Play

A Conceptual Framework for Life-Cycle Health Technology Assessment

Methods for Early Assessment of the Societal Value of Health Technologies: A Scoping Review and Proposal for Classification

August 2022

Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report

Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials

Public Preferences for Policies to Promote COVID-19 Vaccination Uptake: A Discrete Choice Experiment in The Netherlands

September 2022

Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis

Where Are Populations Aging Better? A Global Comparison of Healthy Aging Across Organization for Economic Cooperation and Development Countries

Toward System-Wide Implementation of Patient-Reported Outcome Measures: A Framework for Countries, States, and Regions

Did the Integrated Urban and Rural Resident Basic Medical Insurance Improve Benefit Equity in China?

Should We Consider Including a Value for “Hope” as an Additional Benefit Within Health Technology Assessment?

October 2022

HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force

Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies 

November 2022

Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology

A Pragmatic Guide to Assessing Real Option Value for Medical Technologies

No Time to Waste: An Appraisal of Value at the End of Life

December 2022

Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?

Preference Variation: Where Does Health Risk Attitude Come Into the Equation?

A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 2—Data From Nonwearables